ATOS - Atossa Therapeutics, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
1.03 0.02 (1.94%)	---	---	---	0.02 (1.94%)	0.02 (1.92%)	0.01 (0.96%)	0.01 (0.96%)

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: AfterHours

Earnings & Ratios

Basic EPS:: -0.07
Diluted EPS:: -0.07
Basic P/E:: -15.0
Diluted P/E:: -15.0
RSI(14) 1m:: 66.67
VWAP:: 1.05
RVol:: 0.5902

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	1.05 +0.02 (+1.45%)	Oct 15 13:58
1m	Price decrease 1m	1.05 -0.02 (-1.86%)	Oct 15 11:48
1m	Price increase 1m	1.08 +0.02 (+1.9%)	Oct 15 10:33
1m	Price decrease 1m	1.05 -0.02 (-1.87%)	Oct 15 10:14